Amphstar Pharmaceuticals vs Corcept Therapeutics
Corcept Therapeutics reported revenue of $761 million in fiscal 2025, about the same as Amphstar Pharmaceuticals' $720 million in fiscal 2025. Amphstar Pharmaceuticals' revenue fell 1.6% in its latest year, and Corcept Therapeutics' grew 12.8%. Amphstar Pharmaceuticals had an operating margin of 19.5%, against 5.9% at Corcept Therapeutics. Free cash flow was $121 million at Amphstar Pharmaceuticals and $142 million at Corcept Therapeutics.
Side by side
| Amphstar Pharmaceuticals | Corcept Therapeutics | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $720M | $761M |
| Revenue growth | −1.6% | 12.8% |
| Revenue growth a year, last 5 years | 15.5% | 16.6% |
| Gross margin | 49.5% | 98.3% |
| Operating margin | 19.5% | 5.9% |
| Net margin | 13.6% | 13.1% |
| Free cash flow | $121M | $142M |
| Free cash flow margin | 16.8% | 18.6% |
| Return on capital | 9.9% | 15.7% |
| Net debt to EBITDA | 1.7x | −8.1x |
| Dividends and buybacks | $76M | $173M |
| Change in diluted share count | −7.4% | 5.7% |
| Last close | $25.47 | $87.12 |
| P/E at the last close | 15.1× | — |
| Insider trades, last 12 months | sold $1.7 million | bought $3.3 million, sold $96.1 million |
| Piotroski F-score | 6 of 9 | 3 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Amphstar PharmaceuticalsCorcept Therapeutics
Operating margin
Percent of revenue
Amphstar PharmaceuticalsCorcept Therapeutics
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Amphstar PharmaceuticalsCorcept Therapeutics
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Amphstar Pharmaceuticals and Corcept Therapeutics pages.